Related Experiment Video

Updated: Aug 11, 2025

Author Spotlight: Decoding Mitochondrial Aging
08:48

Author Spotlight: Decoding Mitochondrial Aging

Published on: June 30, 2023

4.1K

UBA52 Attunes VDAC1-Mediated Mitochondrial Dysfunction and Dopaminergic Neuronal Death

Shubhangini Tiwari1, Abhishek Singh1,2, Parul Gupta1,2

  • 1Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow 226031, India.

ACS Chemical Neuroscience
|February 9, 2023
PubMed

Insights

The ubiquitin gene UBA52 protects neurons by maintaining mitochondrial homeostasis and preventing cell death. This finding offers new insights into combating dopaminergic cell loss in Parkinson's disease.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Mitochondrial homeostasis is crucial for cellular functions, including energy metabolism, calcium buffering, and apoptosis.
  • Dysregulation of mitochondrial function is implicated in neurodegenerative diseases like Parkinson's disease (PD).

Purpose of the Study:

  • To investigate the role of the ubiquitin-encoding gene UBA52 in neuronal mitochondrial physiology.
  • To explore the potential of UBA52 as a therapeutic target for Parkinson's disease.

Main Methods:

  • Transient expression of Myc-UBA52 in neuronal cells.
  • Assessment of reactive oxygen species, nitrite levels, and glutathione levels.
  • Mass spectrometry and coimmunoprecipitation to identify protein interactions.
  • In vitro ubiquitylation assays.
  • Measurement of mitochondrial membrane potential, complex I activity, and cytochrome c translocation.

Main Results:

  • Myc-UBA52 expression inhibited rotenone-induced oxidative stress and protected glutathione levels.
  • UBA52 was found to interact with VDAC1, a mitochondrial outer membrane protein, and facilitate its ubiquitylation via CHIP.
  • Overexpression of Myc-UBA52 improved mitochondrial function, enhanced cell viability, and prevented alterations in mitochondrial parameters.
  • Myc-UBA52 expression protected against apoptotic and autophagic cell death.

Conclusions:

  • UBA52 plays a significant role in maintaining mitochondrial homeostasis in neurons.
  • The interaction between UBA52 and VDAC1 is critical for UBA52's protective effects.
  • UBA52 demonstrates potential as a therapeutic strategy to prevent dopaminergic cell death in Parkinson's disease.
Keywords:
Parkinson’s diseaseautophagic cell deathmitochondrial homeostasisubiquitin-60S ribosomal protein L40 (UBA52)ubiquitylationvoltage-dependent anion channel 1 (VDAC1)

More Related Videos

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

1.7K
Primary Culture of Mouse Dopaminergic Neurons11:58

Primary Culture of Mouse Dopaminergic Neurons

Published on: September 8, 2014

38.2K

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.5K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.7K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
396
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
330